Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Profit After Tax: 2009-2025

Historic Profit After Tax for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$651,482.

  • China Pharma Holdings' Profit After Tax rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.46%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
  • Latest data reveals that China Pharma Holdings reported Profit After Tax of -$651,482 as of Q3 2025, which was down 23.30% from -$528,367 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Profit After Tax high stood at -$475,976 for Q1 2023, and its period low was -$1.4 million during Q2 2024.
  • For the 3-year period, China Pharma Holdings' Profit After Tax averaged around -$890,457, with its median value being -$800,000 (2025).
  • Its Profit After Tax has fluctuated over the past 5 years, first slumped by 6,418.56% in 2021, then skyrocketed by 63.26% in 2025.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Profit After Tax stood at -$980,719 in 2021, then dropped by 28.90% to -$1.3 million in 2022, then grew by 2.53% to -$1.2 million in 2023, then rose by 0.63% to -$1.2 million in 2024, then skyrocketed by 41.72% to -$651,482 in 2025.
  • Its Profit After Tax was -$651,482 in Q3 2025, compared to -$528,367 in Q2 2025 and -$800,000 in Q1 2025.